Progress of Cancer Stem Cells in Retinoblastoma

Nan      Wang; Jian-Min      Ma
doi:10.2174/011574888X252989230921065809
Abstract

The theory of cancer stem cells is a breakthrough discovery that offers exciting possibilities for comprehending the biological behavior of tumors. More and more evidence suggests that retinoblastoma cancer stem cells promote tumor growth and are likely to be the origin of tumor formation, drug resistance, recurrence, and metastasis. At present, some progress has been made in the verification, biological behavior, and drug resistance mechanism of retinoblastoma cancer stem cells. This article aims to review the relevant research and explore future development direction.
Keywords: Retinoblastoma, cancer stem cells, drug resistance, Wnt pathway, targeted therapy, tumor.
« Previous Next »
Graphical Abstract

[1]
Tang Z, Ma H, Mao Y, et al. Identification of stemness in primary retinoblastoma cells by analysis of stem-cell phenotypes and tumorigenicity with culture and xenograft models. Exp Cell Res  2019; 379(1): 110-8.
 [http://dx.doi.org/10.1016/j.yexcr.2019.03.034] [PMID: 30935947]

[2]
Deegan WF. Emerging strategies for the treatment of retinoblastoma. Curr Opin Ophthalmol  2003; 14(5): 291-5.
 [http://dx.doi.org/10.1097/00055735-200310000-00010] [PMID: 14502057]

[3]
Knudson AG Jr. Mutation and cancer: Statistical study of retinoblastoma. Proc Natl Acad Sci  1971; 68(4): 820-3.
 [http://dx.doi.org/10.1073/pnas.68.4.820] [PMID: 5279523]

[4]
Sachdeva UM, O’Brien JM. Understanding pRb: Toward the necessary development of targeted treatments for retinoblastoma. J Clin Invest  2012; 122(2): 425-34.
 [http://dx.doi.org/10.1172/JCI57114] [PMID: 22293180]

[5]
Wong JR, Morton LM, Tucker MA, et al. Risk of subsequent malignant neoplasms in long-term hereditary retinoblastoma survivors after chemotherapy and radiotherapy. J Clin Oncol  2014; 32(29): 3284-90.
 [http://dx.doi.org/10.1200/JCO.2013.54.7844] [PMID: 25185089]

[6]
Cruz-Gálvez CC, Ordaz-Favila JC, Villar-Calvo VM, Cancino-Marentes ME, Bosch-Canto V. Retinoblastoma: Review and new insights. Front Oncol  2022; 12: 963780.
 [http://dx.doi.org/10.3389/fonc.2022.963780] [PMID: 36408154]

[7]
Abramson DH, Frank CM. Second nonocular tumors in survivors of bilateral retinoblastoma. Ophthalmology  1998; 105(4): 573-80.
 [http://dx.doi.org/10.1016/S0161-6420(98)94006-4] [PMID: 9544627]

[8]
Rushlow DE, Mol BM, Kennett JY, et al. Characterisation of retinoblastomas without RB1 mutations: Genomic, gene expression, and clinical studies. Lancet Oncol  2013; 14(4): 327-34.
 [http://dx.doi.org/10.1016/S1470-2045(13)70045-7] [PMID: 23498719]

[9]
Cassoux N, Lumbroso L, Levy-Gabriel C, Aerts I, Doz F, Desjardins L. Retinoblastoma: Update on current management. Asia Pac J Ophthalmol  2017; 6(3): 290-5.
 [PMID: 28558178]

[10]
Dimaras H, Corson TW, Cobrinik D, et al. Retinoblastoma. Nat Rev Dis Primers  2015; 1(1): 15021.
 [http://dx.doi.org/10.1038/nrdp.2015.21] [PMID: 27189421]

[11]
Chantada GL, Qaddoumi I, Canturk S, et al. Strategies to manage retinoblastoma in developing countries. Pediatr Blood Cancer  2011; 56(3): 341-8.
 [http://dx.doi.org/10.1002/pbc.22843] [PMID: 21225909]

[12]
Warda O, Naeem Z, Roelofs KA, Sagoo MS, Reddy MA. Retinoblastoma and vision. Eye  2022; 37(5): 797-808.
 [PMID: 34987197]

[13]
Zhou C, Wen X, Ding Y, et al. Eye-preserving therapies for advanced retinoblastoma. Ophthalmology  2022; 129(2): 209-19.
 [http://dx.doi.org/10.1016/j.ophtha.2021.09.002] [PMID: 34536465]

[14]
Rodriguez-Galindo C, Wilson MW, Haik BG, et al. Treatment of intraocular retinoblastoma with vincristine and carboplatin. J Clin Oncol  2003; 21(10): 2019-25.
 [http://dx.doi.org/10.1200/JCO.2003.09.103] [PMID: 12743157]

[15]
Batlle E, Clevers H. Cancer stem cells revisited. Nat Med  2017; 23(10): 1124-34.
 [http://dx.doi.org/10.1038/nm.4409] [PMID: 28985214]

[16]
Hewitt HB. Studies of the dissemination and quantitative transplantation of a lymphocytic leukaemia of CBA mice. Br J Cancer  1958; 12(3): 378-401.
 [http://dx.doi.org/10.1038/bjc.1958.47] [PMID: 13596492]

[17]
Lapidot T, Sirard C, Vormoor J, et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature  1994; 367(6464): 645-8.
 [http://dx.doi.org/10.1038/367645a0] [PMID: 7509044]

[18]
Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature  2001; 414(6859): 105-11.
 [http://dx.doi.org/10.1038/35102167] [PMID: 11689955]

[19]
Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci  2003; 100(7): 3983-8.
 [http://dx.doi.org/10.1073/pnas.0530291100] [PMID: 12629218]

[20]
Clarke MF, Dick JE, Dirks PB, et al. Cancer stem cells--perspectives on current status and future directions: AACR Workshop on cancer stem cells. Cancer Res  2006; 66(19): 9339-44.
 [http://dx.doi.org/10.1158/0008-5472.CAN-06-3126] [PMID: 16990346]

[21]
Driessens G, Beck B, Caauwe A, Simons BD, Blanpain C. Defining the mode of tumour growth by clonal analysis. Nature  2012; 488(7412): 527-30.
 [http://dx.doi.org/10.1038/nature11344] [PMID: 22854777]

[22]
Kreso A, Dick JE. Evolution of the cancer stem cell model. Cell Stem Cell  2014; 14(3): 275-91.
 [http://dx.doi.org/10.1016/j.stem.2014.02.006] [PMID: 24607403]

[23]
Jia M, Wei Z, Liu P, Zhao X. Silencing of ABCG2 by MicroRNA-3163 inhibits multidrug resistance in retinoblastoma cancer stem cells. J Korean Med Sci  2016; 31(6): 836-42.
 [http://dx.doi.org/10.3346/jkms.2016.31.6.836] [PMID: 27247490]

[24]
Han J, Won M, Kim JH, et al. Cancer stem cell-targeted bio-imaging and chemotherapeutic perspective. Chem Soc Rev  2020; 49(22): 7856-78.
 [http://dx.doi.org/10.1039/D0CS00379D] [PMID: 32633291]

[25]
Najafi M, Mortezaee K, Majidpoor J. Cancer stem cell (CSC) resistance drivers. Life Sci  2019; 234: 116781.
 [http://dx.doi.org/10.1016/j.lfs.2019.116781] [PMID: 31430455]

[26]
Baumann M, Krause M, Hill R. Exploring the role of cancer stem cells in radioresistance. Nat Rev Cancer  2008; 8(7): 545-54.
 [http://dx.doi.org/10.1038/nrc2419] [PMID: 18511937]

[27]
Marx J. Cancer research. Mutant stem cells may seed cancer. Science  2003; 301(5638): 1308-10.
 [http://dx.doi.org/10.1126/science.301.5638.1308] [PMID: 12958339]

[28]
Soda Y, Marumoto T, Friedmann-Morvinski D, et al. Transdifferentiation of glioblastoma cells into vascular endothelial cells. Proc Natl Acad Sci  2011; 108(11): 4274-80.
 [http://dx.doi.org/10.1073/pnas.1016030108] [PMID: 21262804]

[29]
Seigel GM. Differentiation potential of human retinoblastoma cells. Curr Pharm Biotechnol  2011; 12(2): 213-6.
 [http://dx.doi.org/10.2174/138920111794295846] [PMID: 21044005]

[30]
Shimokawa M, Ohta Y, Nishikori S, et al. Visualization and targeting of LGR5+ human colon cancer stem cells. Nature  2017; 545(7653): 187-92.
 [http://dx.doi.org/10.1038/nature22081] [PMID: 28355176]

[31]
Prasetyanti PR, Medema JP. Intra-tumor heterogeneity from a cancer stem cell perspective. Mol Cancer  2017; 16(1): 41.
 [http://dx.doi.org/10.1186/s12943-017-0600-4] [PMID: 28209166]

[32]
Quayle LA, Ottewell PD, Holen I. Chemotherapy resistance and stemness in mitotically quiescent human breast cancer cells identified by fluorescent dye retention. Clin Exp Metastasis  2018; 35(8): 831-46.
 [http://dx.doi.org/10.1007/s10585-018-9946-2] [PMID: 30377878]

[33]
Sancho P, Burgos-Ramos E, Tavera A, et al. MYC/PGC-1α balance determines the metabolic phenotype and plasticity of pancreatic cancer stem cells. Cell Metab  2015; 22(4): 590-605.
 [http://dx.doi.org/10.1016/j.cmet.2015.08.015] [PMID: 26365176]

[34]
Yokoi E, Mabuchi S, Shimura K, et al. Lurbinectedin (PM01183), a selective inhibitor of active transcription, effectively eliminates both cancer cells and cancer stem cells in preclinical models of uterine cervical cancer. Invest New Drugs  2019; 37(5): 818-27.
 [http://dx.doi.org/10.1007/s10637-018-0686-6] [PMID: 30374654]

[35]
Oshimori N, Oristian D, Fuchs E. TGF-β promotes heterogeneity and drug resistance in squamous cell carcinoma. Cell  2015; 160(5): 963-76.
 [http://dx.doi.org/10.1016/j.cell.2015.01.043] [PMID: 25723170]

[36]
Kurtova AV, Xiao J, Mo Q, et al. Blocking PGE2-induced tumour repopulation abrogates bladder cancer chemoresistance. Nature  2015; 517(7533): 209-13.
 [http://dx.doi.org/10.1038/nature14034] [PMID: 25470039]

[37]
Creighton CJ, Li X, Landis M, et al. Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. Proc Natl Acad Sci  2009; 106(33): 13820-5.
 [http://dx.doi.org/10.1073/pnas.0905718106] [PMID: 19666588]

[38]
Ma B, Lei X, Guan Y, et al. Maintenance of retinal cancer stem cell-like properties through long-term serum-free culture from human retinoblastoma. Oncol Rep  2011; 26(1): 135-43. [J].
 [PMID: 21573498]

[39]
Kelland L. Targeting the limitless replicative potential of cancer: The telomerase/telomere pathway. Clin Cancer Res  2007; 13(17): 4960-3.
 [http://dx.doi.org/10.1158/1078-0432.CCR-07-0422] [PMID: 17785545]

[40]
Hu Y, Guo R, Wei J, et al. Effects of PI3K inhibitor NVP-BKM120 on overcoming drug resistance and eliminating cancer stem cells in human breast cancer cells. Cell Death Dis  2015; 6(12): e2020.
 [http://dx.doi.org/10.1038/cddis.2015.363] [PMID: 26673665]

[41]
Zhang M, Mathur A, Zhang Y, et al. Mithramycin represses basal and cigarette smoke-induced expression of ABCG2 and inhibits stem cell signaling in lung and esophageal cancer cells. Cancer Res  2012; 72(16): 4178-92.
 [http://dx.doi.org/10.1158/0008-5472.CAN-11-3983] [PMID: 22751465]

[42]
Kipp AP, Deubel S, Arnér ESJ, Johansson K. Time- and cell-resolved dynamics of redox-sensitive Nrf2, HIF and NF-κB activities in 3D spheroids enriched for cancer stem cells. Redox Biol  2017; 12: 403-9.
 [http://dx.doi.org/10.1016/j.redox.2017.03.013] [PMID: 28319891]

[43]
Chefetz I, Grimley E, Yang K, et al. A Pan-ALDH1A inhibitor induces necroptosis in ovarian cancer stem-like cells. Cell Rep  2019; 26(11): 3061-3075.e6.
 [http://dx.doi.org/10.1016/j.celrep.2019.02.032] [PMID: 30865894]

[44]
Yip NC, Fombon IS, Liu P, et al. Disulfiram modulated ROS–MAPK and NFκB pathways and targeted breast cancer cells with cancer stem cell-like properties. Br J Cancer  2011; 104(10): 1564-74.
 [http://dx.doi.org/10.1038/bjc.2011.126] [PMID: 21487404]

[45]
Najafi M, Mortezaee K, Ahadi R. Cancer stem cell (a)symmetry & plasticity: Tumorigenesis and therapy relevance. Life Sci  2019; 231: 116520.
 [http://dx.doi.org/10.1016/j.lfs.2019.05.076] [PMID: 31158379]

[46]
Bayik D, Lathia JD. Cancer stem cell–immune cell crosstalk in tumour progression. Nat Rev Cancer  2021; 21(8): 526-36.
 [http://dx.doi.org/10.1038/s41568-021-00366-w] [PMID: 34103704]

[47]
Seigel GM, Campbell LM, Narayan M, Gonzalez-Fernandez F. Cancer stem cell characteristics in retinoblastoma. Mol Vis  2005; 11(11): 729-37.
 [PMID: 16179903]

[48]
Gail MS, Abigail SH, Arupa G, Lorrie MM, Gonzalez-Fernandez F. Human embryonic and neuronal stem cell markers in retinoblastoma. Mol Vis  2007; 13: 823-32.

[49]
Zhong X, Li Y, Peng F, et al. Identification of tumorigenic retinal stem like cells in human solid retinoblastomas. Int J Cancer  2007; 121(10): 2125-31.
 [http://dx.doi.org/10.1002/ijc.22880] [PMID: 17565741]

[50]
Vemuganti GK, Nair RM, Revu NVL, et al. A short-term chick embryo in vivo xenograft model to study retinoblastoma cancer stem cells. Indian J Ophthalmol  2022; 70(5): 1703-11.
 [http://dx.doi.org/10.4103/ijo.IJO_2348_21] [PMID: 35502056]

[51]
Austin Doyle L, Ross DD. Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2). Oncogene  2003; 22(47): 7340-58.
 [http://dx.doi.org/10.1038/sj.onc.1206938] [PMID: 14576842]

[52]
Bhattacharya S, Das A, Mallya K, Ahmad I. Maintenance of retinal stem cells by Abcg2 is regulated by notch signaling. J Cell Sci  2007; 120(15): 2652-62.
 [http://dx.doi.org/10.1242/jcs.008417] [PMID: 17635990]

[53]
Mohan A, Kandalam M, Ramkumar HL, Gopal L, Krishnakumar S. Stem cell markers: ABCG2 and MCM2 expression in retinoblastoma. Br J Ophthalmol  2006; 90(7): 889-93.
 [http://dx.doi.org/10.1136/bjo.2005.089219] [PMID: 16556617]

[54]
Singh SK, Clarke ID, Terasaki M, et al. Identification of a cancer stem cell in human brain tumors. Cancer Res  2003; 63(18): 5821-8. [J].
 [PMID: 14522905]

[55]
Jang JW, Song Y, Kim SH, Kim J, Seo HR. Potential mechanisms of CD133 in cancer stem cells. Life Sci  2017; 184: 25-9.
 [http://dx.doi.org/10.1016/j.lfs.2017.07.008] [PMID: 28697984]

[56]
Hu H, Deng F, Liu Y, et al. Characterization and retinal neuron differentiation of WERI-Rb1 cancer stem cells. Mol Vis  2012; 18: 2388-97. [J].
 [PMID: 23049239]

[57]
Nair RM, Balla MMS, Khan I, Kalathur RKR, Kondaiah P, Vemuganti GK. In vitro characterization of CD133lo cancer stem cells in Retinoblastoma Y79 cell line. BMC Cancer  2017; 17(1): 779.
 [http://dx.doi.org/10.1186/s12885-017-3750-2] [PMID: 29162051]

[58]
Balla MMS, Vemuganti GK, Kannabiran C, Honavar SG, Murthy R. Phenotypic characterization of retinoblastoma for the presence of putative cancer stem-like cell markers by flow cytometry. Invest Ophthalmol Vis Sci  2009; 50(4): 1506-14.
 [http://dx.doi.org/10.1167/iovs.08-2356] [PMID: 19029022]

[59]
Gires O, Pan M, Schinke H, Canis M, Baeuerle PA. Expression and function of epithelial cell adhesion molecule EpCAM: where are we after 40 years? Cancer Metastasis Rev  2020; 39(3): 969-87.
 [http://dx.doi.org/10.1007/s10555-020-09898-3] [PMID: 32507912]

[60]
Mitra M, Kandalam M, Harilal A, et al. EpCAM is a putative stem marker in retinoblastoma and an effective target for T-cell-mediated immunotherapy. Mol Vis  2012; 18: 290-308.
 [PMID: 22328825]

[61]
Krishnakumar S, Mohan A, Mallikarjuna K, et al. EpCAM expression in retinoblastoma: A novel molecular target for therapy. Invest Ophthalmol Vis Sci  2004; 45(12): 4247-50.
 [http://dx.doi.org/10.1167/iovs.04-0591] [PMID: 15557427]

[62]
Mitra M, Kandalam M, Verma RS, UmaMaheswari K, Krishnakumar S. Genome-wide changes accompanying the knockdown of Ep-CAM in retinoblastoma. Mol Vis  2010; 16: 828-42. [J].
 [PMID: 20461151]

[63]
Qiang L, Yang Y, Ma YJ, et al. Isolation and characterization of cancer stem like cells in human glioblastoma cell lines. Cancer Lett  2009; 279(1): 13-21.
 [http://dx.doi.org/10.1016/j.canlet.2009.01.016] [PMID: 19232461]

[64]
Zhou S, Schuetz JD, Bunting KD, et al. The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype. Nat Med  2001; 7(9): 1028-34.
 [http://dx.doi.org/10.1038/nm0901-1028] [PMID: 11533706]

[65]
Reya T, Clevers H. Wnt signalling in stem cells and cancer. Nature  2005; 434(7035): 843-50.
 [http://dx.doi.org/10.1038/nature03319] [PMID: 15829953]

[66]
Zhan T, Rindtorff N, Boutros M. Wnt signaling in cancer. Oncogene  2017; 36(11): 1461-73.
 [http://dx.doi.org/10.1038/onc.2016.304] [PMID: 27617575]

[67]
Silva AK, Yi H, Hayes SH, Seigel GM, Hackam AS. Lithium chloride regulates the proliferation of stem-like cells in retinoblastoma cell lines: A potential role for the canonical Wnt signaling pathway. Mol Vis  2010; 16: 36-45. [J].
 [PMID: 20069066]

[68]
Tell S, Yi H, Jockovich ME, Murray TG, Hackam AS. The Wnt signaling pathway has tumor suppressor properties in retinoblastoma. Biochem Biophys Res Commun  2006; 349(1): 261-9.
 [http://dx.doi.org/10.1016/j.bbrc.2006.08.044] [PMID: 16930536]

[69]
Novak D, Hüser L, Elton JJ, Umansky V, Altevogt P, Utikal J. SOX2 in development and cancer biology. Semin Cancer Biol  2020; 67(Pt 1): 74-82.
 [http://dx.doi.org/10.1016/j.semcancer.2019.08.007] [PMID: 31412296]

[70]
Moya IM, Halder G. Hippo–YAP/TAZ signalling in organ regeneration and regenerative medicine. Nat Rev Mol Cell Biol  2019; 20(4): 211-26.
 [http://dx.doi.org/10.1038/s41580-018-0086-y] [PMID: 30546055]

[71]
Zhou B, Lin W, Long Y, et al. Notch signaling pathway: Architecture, disease, and therapeutics. Signal Transduct Target Ther  2022; 7(1): 95.
 [http://dx.doi.org/10.1038/s41392-022-00934-y] [PMID: 35332121]

[72]
Xiao W, Chen X, He M. Inhibition of the Jagged/Notch pathway inhibits retinoblastoma cell proliferation via suppressing the PI3K/Akt, Src, p38MAPK and Wnt/β-catenin signaling pathways. Mol Med Rep  2014; 10(1): 453-8.
 [http://dx.doi.org/10.3892/mmr.2014.2213] [PMID: 24805975]

[73]
Asnaghi L, Tripathy A, Yang Q, et al. Targeting Notch signaling as a novel therapy for retinoblastoma. Oncotarget  2016; 7(43): 70028-44.
 [http://dx.doi.org/10.18632/oncotarget.12142] [PMID: 27661116]

[74]
Zhao N, Zhou L, Lu Q, et al. SOX2 maintains the stemness of retinoblastoma stem-like cells through Hippo/YAP signaling pathway. Exp Eye Res  2021; 214: 108887.

[75]
Dong C, Liu S, Lv Y, et al. Long non-coding RNA HOTAIR regulates proliferation and invasion via activating Notch signalling pathway in retinoblastoma. J Biosci  2016; 41(4): 677-87.
 [http://dx.doi.org/10.1007/s12038-016-9636-7] [PMID: 27966488]

[76]
Gao Y, Luo X, Zhang J. LincRNA-ROR is activated by H3K27 acetylation and induces EMT in retinoblastoma by acting as a sponge of miR-32 to activate the Notch signaling pathway. Cancer Gene Ther  2021; 28(1-2): 42-54.
 [http://dx.doi.org/10.1038/s41417-020-0181-z] [PMID: 32439866]

[77]
Zhang S, Cui Z. MicroRNA 34b 5p inhibits proliferation, stemness, migration and invasion of retinoblastoma cells via Notch signaling. Exp Ther Med  2021; 21(3): 255.
 [http://dx.doi.org/10.3892/etm.2021.9686] [PMID: 33603862]

[78]
Ahmed F, Ali MJ, Kondapi AK. Carboplatin loaded protein nanoparticles exhibit improve anti-proliferative activity in retinoblastoma cells. Int J Biol Macromol  2014; 70: 572-82.
 [http://dx.doi.org/10.1016/j.ijbiomac.2014.07.041] [PMID: 25088498]

[79]
Narayana RVL, Jana P, Tomar N, et al. Carboplatin- and etoposide-loaded lactoferrin protein nanoparticles for targeting cancer stem cells in retinoblastoma in vitro. Invest Ophthalmol Vis Sci  2021; 62(14): 13.
 [http://dx.doi.org/10.1167/iovs.62.14.13] [PMID: 34784412]

[80]
Katchinskiy N, Godbout R, Hatef A, Elezzabi AY. Anti-EpCAM gold nanorods and femtosecond laser pulses for targeted lysis of retinoblastoma. Adv Ther  2018; 1(1): 1800009.
 [http://dx.doi.org/10.1002/adtp.201800009]
Rights & Permissions Print Cite
Article Metrics
34
2
Journal Information
For Authors
For Editors
For Reviewers
Explore Articles
Open Access
Open Access Articles
For Visitors
DOI https://dx.doi.org/10.2174/011574888X252989230921065809	Print ISSN 1574-888X
Publisher Name Bentham Science Publisher	Online ISSN 2212-3946
Current Stem Cell Research & Therapy

Progress of Cancer Stem Cells in Retinoblastoma

Abstract

Graphical Abstract

Related Journals

Related Books

Related Articles
